Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) (Walvax Biotechnology)

重组新型冠状病毒疫苗（黑猩猩腺病毒载体）

Report date: 2024/04/26 17:00:42

Base Information

Drug NameRecombinant COVID-19 Vaccine (chimpanzee adenovirus vector) (Walvax Biotechnology)

Drug Alias NameN/A

ClassificationVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccineVaccines > Development/production technology > Recombinant vector vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaDiscontinued

Originator CompaniesWalvax Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesWalvax Biotechnology Co Ltd

Active IndicationsN/A

Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A